Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 7001–7050 of 18650
On January 9, 2024, LivePerson, Inc. (the “ Company ”) announced that the Board of Directors of the Company (the “ Board ”) has appointed Anthony John Sabino to serve as Chief Executive Officer (principal executive officer) of the Company after a search process conducted by a search committee comprised of independent directors.
the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) appointed Vered Bisker-Leib, PhD as Chief Executive Officer of the Company and a member the Board, each effective January 9, 2024.
approved the proposed terms under which Adrian J. Downes will step down as Chief Financial Officer.
On January 6, 2024, the Board of Directors accepted the resignation of Mr. William Schara as Chief Executive Officer (“CEO”) and President of the Company, effective immediately, to focus on other business interests.
Mr. Steve Vincent has been appointed acting interim CEO, effective immediately.
On January 9, 2024, Hans Thomas and 10X Capital Venture Acquisition Corp. III (“10X III”) agreed that Mr. Thomas will no longer serve as 10X III’s Chief Executive Officer, effective January 9, 2024.
On January 9, 2024, the Board appointed David Weisburd as 10X III’s Chief Executive Officer, effective January 9, 2024.
In connection with the consummation of the Merger, as of the Effective Time, each of James Stark (Chief Financial Officer), James Herbert (Chief Human Resources Officer), Grant Kadavy (Executive Vice President-Commercial Operations), Chris Osowski (Executive Vice President-Operations and Technology) and Patrich Simpkins (Chief Transformation Officer) ceased to serve as officers of the General Partner.
On January 5, 2024, Jason Roswig informed Skillz Inc. (the “Company”) of his decision to step down from his position as the President and Chief Financial Officer.
Effective January 8, 2024 (the “Effective Date”), Gaetano Franceschi, 51, will serve as the Chief Financial Officer of the Company.
Mr. David Lazar, president, chief executive officer, treasurer, chief financial officer, Secretary and the sole member of the Board of Directors (the “Board”), resigned from all of his positions with the Company and the resignations became effective on December 28, 2023.
On January 8, 2024 AllianceBernstein L.P. (" ABLP ") and AllianceBernstein Holding L.P. (together with ABLP, " AB ") announced the appointment of Jackie Marks as Chief Financial Officer (" CFO "), effective March 1, 2024.
the Board of Directors of the Company (the “Board”) unanimously approved the appointment of Joanna Geraghty, the Company’s President and Chief Operating Officer, as Chief Executive Officer, effective as of the Transition Date.
On January 7, 2024, Robin Hayes, Chief Executive Officer of JetBlue Airways Corporation (“JetBlue” or the “Company”), notified the Company of his decision to retire from his position, effective February 12, 2024 (the “Transition Date”).
Effective upon the employment of Mr. Adams, Jason Cohenour will cease service as Interim Chief Executive Officer, but will continue to serve as a member of the Company’s Board of Directors.
Effective January 22, 2024, Christopher R. Adams, age 57, will commence employment as President and Chief Executive Officer of CalAmp Corp. (the “Company”) and will be appointed a member of the Company’s Board of Directors.
Concurrently with such appointment, the Board removed Brian Ford from the position of interim-Chief Financial Officer.
On January 5, 2024, the Board of Directors (the “Board”) of Acasti Pharma Inc. (the “Company”) approved the appointment of Robert J. DelAversano, the Company's Vice President, Finance, to the roles of principal financial officer and principal accounting officer of the Company, effective immediately.
On January 4, 2024, Roadzen Inc. (the "Company") appointed Jean-No ë l Gallardo to serve as the Company's Chief Financial Officer ("CFO").
its President and Chief Executive Officer, Nadim Yared, provided notice to the Company’s Board of Directors (the “Board”) of his plans to retire upon the completion of a deliberate succession process and the appointment of a successor.
On January 8, 2024 AllianceBernstein L.P. (“ ABLP ”) and AllianceBernstein Holding L.P. (together with ABLP, “ AB ”) announced the appointment of Jackie Marks as Chief Financial Officer (“ CFO ”), effective March 1, 2024.
On January 5, 2024, the Board of Directors appointed Joseph F. Bruderek Jr. as Chief Financial Officer of the Company effective as of April 1, 2024
consistent with his retirement plans, Mr. Childress will cease to be Chief Financial Officer at that time.
On January 3, 2024, the Board of Directors of the Company (the “Board”) appointed Mr. Christopher Metz as the Company’s President and Chief Executive Officer, effective as of January 15, 2024 (the “Effective Date”).
Mr. Metz succeeds Mr. John Merris, who has mutually separated from the Company as a Director and the President and Chief Executive Officer of the Company, as of the Effective Date.
On January 8, 2024, Mid Penn Bancorp, Inc. (the “Company”) announced the appointment of Justin T. Webb, the Company’s Senior Executive Vice President and Chief Operating Officer having over two decades of banking experience, to the position of Senior Executive Vice President and Chief Financial Officer.
At its meeting held on December 13, 2023, the Company’s Board of Directors appointed Mr. Glover as the Company’s new Executive Vice President & Chief Financial Officer, effective January 22, 2024.
On January 7, 2024, Jeff Lawson resigned as the Company’s Chief Executive Officer (“ CEO ”) and as a member of the Company’s Board of Directors (the “ Board ”) and as Board Chair, in each case, effective January 8, 2024.
On January 7, 2024, the Board appointed Khozema Shipchandler, the Company’s President, Twilio Communications, as CEO of the Company and as a member of the Board, effective January 8, 2024.
On January 8, 2024, the Board of Directors (the “ Board ”) of the Company appointed Anastasia Mironova to the positions of Interim Chief Financial Officer, Treasurer and Secretary of the Company, effective as of the effective date of Mr. Calace’s resignation.
On January 2, 2024, John Calace, the Chief Financial Officer, Treasurer and Secretary of Apollo Realty Income Solutions, Inc. (the “ Company ”), informed the Company of his intention to resign from the Company.
Mr. Crager will step down as chief executive officer of Envestnet and each of its subsidiaries on March 31, 2024.
Mr. Fox will serve as Interim CEO commencing on April 1, 2024.
On January 5, 2024, Jason Bonfigt submitted to the Board of Directors of Sunworks, Inc. (the “Company”) his resignation from his position as Chief Financial Officer of the Company, effective January 5, 2024.
Lubi Kutua, the Company’s current Chief Financial Officer, Treasurer and principal financial officer, will assume the duties of principal accounting officer effective January 6, 2024 until a replacement is appointed.
Charley Jemley’s planned departure from his current role as Chief Financial Officer.
Joshua Guenser will join the Company as Incoming Chief Financial Officer on or about February 19, 2024 in concert with Charley Jemley’s planned departure from his current role as Chief Financial Officer.
Mr. Mariani’s severance benefits in connection with his departure include a severance amount equal to 12 months of his current base compensation and COBRA benefits for 12 months after he ceased to be an employee of the Company on December 22, 2023 (the “Separation Date”).
The Board of Directors (the “Board”) of CVS Health appointed Thomas F. Cowhey to serve as CVS Health’s Executive Vice President and Chief Financial Officer, effective January 5, 2024.
On January 5, 2024, CVS Health also announced that Shawn M. Guertin, who, as previously disclosed, was on a personal leave of absence since October 13, 2023, will step down from his role as CVS Health’s Executive Vice President, Chief Financial Officer and President of Health Services due to family health reasons, effective immediately.
Kevin DeLeon has resigned as our Chief Executive Officer, President, and Principal Financial and Accounting Officer.
Christopher Headrick, James McGinley, Neil Goulden have been appointed to our Board (with Mr. Headrick appointed as the Chairman of the Board).
On July 31, 2023, Basanite, Inc. (the “Company”) entered into an engagement letter with Thomas Richmond to join our Company as acting Interim Chief Executive Officer and as an independent contractor until December 31, 2023. As the engagement letter has not been extended by the Company, Mr. Richmond’s services with Basanite have terminated and he is no longer affiliated with the Company.
Mr. Strang will be replacing Michael Pope, whose last day as an employee of the Company will be January 12, 2024.
On January 4, 2024, the Board of Directors (the “Board”) of the Company appointed Dale Strang, a current member of the Board, to serve as the Company’s interim Chief Executive Officer and principal executive officer, effective immediately.
On January 5, 2024, Twist Bioscience Corporation (the “Company”) announced the appointment of Adam Laponis as the Company’s Chief Financial Officer and principal financial officer, effective January 8, 2024.
As previously reported by the Company in its Form 8-K filed on August 4, 2023 (the “Prior 8-K”), upon commencement of employment by Mr. Laponis, James Thorburn will no longer serve as the Company’s Chief Financial Officer.
Prior to resigning, the Board appointed Andrew Cohen, Daniel Wainstein, Lewis Silberman and Paul Baron to fill the vacancies on the Board created by such resignations and appointed Andrew Cohen as Chief Executive Officer of the Company.
On August 28, 2023, Canoo Inc. (the “ Company ”) announced the appointment of Greg Ethridge as Chief Financial Officer of the Company, effective immediately.
George Courtot resigned as the Company’s Chief Financial Officer
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.